Journal
PHARMACOLOGICAL RESEARCH
Volume 177, Issue -, Pages -Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2022.106133
Keywords
CD44; Neuroinflammation; Glial cells; TLR4; NF-kappa B; Parkinson's disease
Categories
Funding
- National Natural Science Foundation of China [81970747]
- National Key Research and Devel-opment Program of China [2017YFA0701304]
Ask authors/readers for more resources
CD44 plays a crucial role in neuroinflammation and may be involved in the progression of Parkinson's disease. This study reveals that CD44 deficiency can inhibit the expression of proinflammatory cytokines and improve behavioral defects in PD model mice. Neutralization of CD44 with antibodies produces similar effects.
CD44 is a transmembrane protein that transduces extracellular stimuli to immune response. Neuroinflammation is a causative factor in neurodegenerative diseases, such as Parkinson's disease (PD). Owing to its role in inflammation, this study investigated whether CD44 is involved in the pathological progression of PD. Our data showed that CD44 deficiency largely abolished proinflammatory cytokine expression in primary microglia and astrocytes. In PD model mice, CD44 knockout improved behavioral defects, prevented TH loss in the SNpc and striatum, and blocked activation of microglia and astrocytes. Moreover, CD44 neutralization by anti-CD44 antibody recapitulated the phenotypes observed in CD44 knockout mice. Mechanistically, CD44 neutralization blocked TLR4 expression and NF-kappa B p65 nuclear translocation induced by lipopolysaccharide in BV2 cells. Overall, our results indicate that CD44 deficiency has a beneficial role against PD, which is likely due to repression of the TLR4/NF-kappa B axis, leading to reduced neuroinflammation. Therefore, CD44 might be a therapeutic target for the development of anti-PD agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available